MDT-AP-2372
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 148.32
- os_event
- false
- age_years
- 2.82
- sex
- M
- new_clusters
- C4
- umap1_2d
- 3.927285819
- umap2_2d
- 4.134798598
- umap1_3d
- 0.985359555
- umap2_3d
- -0.61308413
- umap3_3d
- -1.590529351
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- ANGIOGENESIS+0.350
- COAGULATION+0.350
- MYOGENESIS+0.280
- PANCREAS_BETA_CELLS+0.280
- ESTROGEN_RESPONSE_LATE+0.270
- KRAS_SIGNALING_UP+0.270
- ALLOGRAFT_REJECTION+0.250
- KRAS_SIGNALING_DN+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
Top 10 suppressed
- MITOTIC_SPINDLE-0.360
- WNT_BETA_CATENIN_SIGNALING-0.350
- PROTEIN_SECRETION-0.330
- TGF_BETA_SIGNALING-0.300
- ANDROGEN_RESPONSE-0.250
- G2M_CHECKPOINT-0.220
- BILE_ACID_METABOLISM-0.150
- UV_RESPONSE_DN-0.150
- HEME_METABOLISM-0.140
- NOTCH_SIGNALING-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2510 | Med | Medulloblastoma | 0.805 |
| 2 | TCGA-60-2720-01A-01R-0851-07 | — | cohortSQ1 | 0.789 |
| 3 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.788 |
| 4 | MDT-AP-2299 | Med | Medulloblastoma | 0.780 |
| 5 | MDT-AP-2153 | Med | Medulloblastoma | 0.777 |
| 6 | TCGA-OL-A5S0-01A-11R-A28M-07 | — | E | 0.776 |
| 7 | TCGA-BH-A5J0-01A-11R-A27Q-07 | — | B | 0.753 |
| 8 | SRR5088877 | — | — | 0.753 |
| 9 | 9a4f9e4a-dc97-4f8d-9075-537b62fb98d3 | — | — | 0.750 |
| 10 | TCGA-XF-A9SU-01A-31R-A39I-07 | — | — | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |